Overview

Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Status:
Completed

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

This protocol is a multicenter, national, open-label, single-arm, non-controlled study designed to establish the efficacy (in terms of response and survival) and safety of panobinostat in combination with idarubicin and cytarabine and in monotherapy in patients with newly-diagnosed AML aged 65 years or older.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

PETHEMA Foundation

Treatments:

Cytarabine
Idarubicin
Panobinostat